Dr. Lal PathLabs Approves FY26 Results, ₹4 Dividend, Acquires SDCPL

Dr. Lal PathLabs Ltd's Board of Directors approved the audited Standalone & Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The board also recommended a final dividend of ₹4 per equity share (40% on face value of ₹10) for FY26, with June 26, 2026, as the record date. Key strategic decisions included the acquisition of a 100% stake in Shahbazkers Diagnostic Centre Private Limited, making it a wholly-owned subsidiary, and the incorporation of a new wholly-owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE. Additionally, the board re-appointed Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as an Independent Director, designated Dr. Reena Nakra and Dr. Saloni Khera as Senior Management Personnel, and re-appointed internal and cost auditors for FY27. The company also allotted 82,750 equity shares under its ESOP 2022.